Metastatic ovarian cancer can be detected in the para-aortic lymph nodes as the ovaries drain to this lymphatic group. This is different from other pelvic organs, which usually drain to the internal and external iliac lymph nodes. The external iliac lymph nodes do not drain the ovary, while the internal iliac lymph nodes do not drain the ovary but drain other pelvic viscera. The deep inguinal lymph nodes drain the clitoris and glans penis, while the superficial inguinal lymph nodes drain the anal canal (below pectinate line), skin below the umbilicus, scrotum, and vulva, but are not significant in the lymphatic drainage of the ovary.

Lymphatic Drainage of Female Reproductive Organs

The lymphatic drainage of the female reproductive organs is a complex system that involves multiple nodal stations. The ovaries drain to the para-aortic lymphatics via the gonadal vessels. The uterine fundus has a lymphatic drainage that runs with the ovarian vessels and may thus drain to the para-aortic nodes. Some drainage may also pass along the round ligament to the inguinal nodes. The body of the uterus drains through lymphatics contained within the broad ligament to the iliac lymph nodes. The cervix drains into three potential nodal stations; laterally through the broad ligament to the external iliac nodes, along the lymphatics of the uterosacral fold to the presacral nodes and posterolaterally along lymphatics lying alongside the uterine vessels to the internal iliac nodes. Understanding the lymphatic drainage of the female reproductive organs is important for the diagnosis and treatment of gynecological cancers.

Understanding Chronic Myeloid Leukaemia and its Management

Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the presence of the Philadelphia chromosome in more than 95% of patients. This chromosome is formed due to a translocation between chromosomes 9 and 22, resulting in the fusion of the ABL proto-oncogene and the BCR gene. The resulting BCR-ABL gene produces a fusion protein that has excessive tyrosine kinase activity.

CML typically affects individuals between the ages of 60-70 years and presents with symptoms such as anaemia, weight loss, sweating, and splenomegaly. The condition is also associated with an increase in granulocytes at different stages of maturation and thrombocytosis. In some cases, CML may undergo blast transformation, leading to acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).

The management of CML involves various treatment options, including imatinib, which is considered the first-line treatment. Imatinib is an inhibitor of the tyrosine kinase associated with the BCR-ABL defect and has a very high response rate in chronic phase CML. Other treatment options include hydroxyurea, interferon-alpha, and allogenic bone marrow transplant. With proper management, individuals with CML can lead a normal life.

To treat solid tumours, immune checkpoint inhibitors are becoming a popular substitute for cytotoxic chemotherapy. These inhibitors function by reactivating and boosting the body’s T-cell population. While radiotherapy harms cancer cell DNA, chemotherapy directly impacts the growth and multiplication of cancer cells.

Understanding Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a type of immunotherapy that is becoming increasingly popular in the treatment of certain types of cancer. Unlike traditional therapies such as chemotherapy, these targeted treatments work by harnessing the body’s natural anti-cancer immune response. They boost the immune system’s ability to attack and destroy cancer cells, rather than directly affecting their growth and proliferation.

T-cells are an essential part of our immune system that helps destroy cancer cells. However, some cancer cells produce high levels of proteins that turn T-cells off. Checkpoint inhibitors block this process and reactivate and increase the body’s T-cell population, enhancing the immune system’s ability to recognize and fight cancer cells.

There are different types of immune checkpoint inhibitors, including Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, and Durvalumab. These drugs block specific proteins found on T-cells and cancer cells, such as CTLA-4, PD-1, and PD-L1. They are administered by injection or intravenous infusion and can be given as a single-agent treatment or combined with chemotherapy or each other.

However, the mechanism of action of these drugs can result in side effects termed ‘Immune-related adverse events’ that are inflammatory and autoimmune in nature. This is because all immune cells are boosted by these drugs, not just the ones that target cancer. The overactive T-cells can produce side effects such as dry, itchy skin and rashes, nausea and vomiting, decreased appetite, diarrhea, tiredness and fatigue, shortness of breath, and a dry cough. Management of such side effects reflects the inflammatory nature, often involving corticosteroids. It is important to monitor liver, kidney, and thyroid function as these drugs can affect these organs.

In conclusion, the early success of immune checkpoint inhibitors in solid tumors has generated tremendous interest in further developing and exploring these strategies across the oncology disease spectrum. Ongoing testing in clinical trials creates new hope for patients affected by other types of disease.

The presence of necrosis in a tumour may indicate that it has become too large for its blood supply, suggesting a high grade tumour. However, when grading breast cancer using the Bloom-Richardson model, nuclear features such as mitoses, coarse chromatin, and pleomorphism are given more weight. The formation of tubular structures is a key indicator of the level of differentiation, with well differentiated tumours showing the presence of tubules.

Tumour Grading and Differentiation

Tumours can be classified based on their degree of differentiation, mitotic activity, and other characteristics. The grading system ranges from grade 1, which is the most differentiated, to grade 3 or 4, which is the least. The evaluation is subjective, but generally, high-grade tumours indicate a poor prognosis or rapid growth.

Glandular epithelium tumours tend to form acinar structures with a central lumen. Well-differentiated tumours exhibit excellent acinar formation, while poorly differentiated tumours appear as clumps of cells around a desmoplastic stroma. Some tumours produce mucous without acinar formation, and these are referred to as mucinous adenocarcinomas. Squamous cell tumours produce structures resembling epithelial cell components, and well-differentiated tumours may also produce keratin, depending on the tissue of origin.

FFP is frozen shortly after collection due to the temperature sensitivity of factors V and VIII.

Blood Products and Cell Saver Devices

Blood products are essential in various medical procedures, especially in cases where patients require transfusions due to anaemia or bleeding. Packed red cells, platelet-rich plasma, platelet concentrate, fresh frozen plasma, and cryoprecipitate are some of the commonly used whole blood fractions. Fresh frozen plasma is usually administered to patients with clotting deficiencies, while cryoprecipitate is a rich source of Factor VIII and fibrinogen. Cross-matching is necessary for all blood products, and cell saver devices are used to collect and re-infuse a patient’s own blood lost during surgery.

Cell saver devices come in two types, those that wash the blood cells before re-infusion and those that do not. The former is more expensive and complicated to operate but reduces the risk of re-infusing contaminated blood. The latter avoids the use of donor blood and may be acceptable to Jehovah’s witnesses. However, it is contraindicated in malignant diseases due to the risk of facilitating disease dissemination.

In some surgical patients, the use of warfarin can pose specific problems and may require the use of specialised blood products. Warfarin reversal can be achieved through the administration of vitamin K, fresh frozen plasma, or human prothrombin complex. Fresh frozen plasma is used less commonly now as a first-line warfarin reversal, and human prothrombin complex is preferred due to its rapid action. However, it should be given with vitamin K as factor 6 has a short half-life.

Docetaxel, a member of the taxane family, disrupts microtubule function by preventing depolymerisation and disassembly. This reduces free tubulin and halts cell division. Irinotecan inhibits topoisomerase I, preventing relaxation of supercoiled DNA, leading to DNA damage and cell death. Methotrexate inhibits dihydrofolate reductase and thymidylate synthesis, slowing and stopping DNA and protein synthesis necessary for normal cell cycle. Cisplatin binds to DNA, cross-linking and inhibiting replication. Doxorubicin stabilises the topoisomerase II complex, inhibiting DNA and RNA synthesis necessary for cell division.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

The prevention of fibrin degradation is achieved by the inhibition of plasmin through the use of tranexamic acid.

Understanding Tranexamic Acid

Tranexamic acid is a synthetic derivative of lysine that acts as an antifibrinolytic. Its primary function is to bind to lysine receptor sites on plasminogen or plasmin, preventing plasmin from degrading fibrin. This medication is commonly prescribed to treat menorrhagia.

In addition to its use in treating menorrhagia, tranexamic acid has been investigated for its role in trauma. The CRASH 2 trial found that administering tranexamic acid within the first 3 hours of bleeding trauma can be beneficial. In cases of major haemorrhage, tranexamic acid is given as an IV bolus followed by an infusion.

Ongoing research is also exploring the potential of tranexamic acid in treating traumatic brain injury. Overall, tranexamic acid is a medication with important applications in managing bleeding disorders and trauma.

DIC is often associated with pregnancy complications such as placental abruption and shock, as well as bleeding from multiple sites and abnormal blood test results. Placenta praevia is characterized by painless vaginal bleeding, but when combined with other haematological results and occurring in a pregnant woman, it may indicate DIC rather than ITP. TTP typically presents with jaundice, low platelets, fever, renal complications, and CNS signs, which are not evident in this case, and clotting test results do not support this diagnosis. While von Willebrand’s disease can cause spontaneous bleeding, the platelet count is usually normal.

Disseminated Intravascular Coagulation: A Condition of Simultaneous Coagulation and Haemorrhage

Disseminated intravascular coagulation (DIC) is a medical condition characterized by simultaneous coagulation and haemorrhage. It is caused by the initial formation of thrombi that consume clotting factors and platelets, ultimately leading to bleeding. DIC can be caused by various factors such as infection, malignancy, trauma, liver disease, and obstetric complications.

Clinically, bleeding is usually the dominant feature of DIC, accompanied by bruising, ischaemia, and organ failure. Blood tests can reveal prolonged clotting times, thrombocytopenia, decreased fibrinogen, and increased fibrinogen degradation products. The treatment of DIC involves addressing the underlying cause and providing supportive management.

In summary, DIC is a serious medical condition that requires prompt diagnosis and management. It is important to identify the underlying cause and provide appropriate treatment to prevent further complications. With proper care and management, patients with DIC can recover and regain their health.

Haemophilia A is the most likely diagnosis for the child based on the family history and presentation of haemarthrosis. Haemophilia is a genetic condition that affects clotting factors VIII or IX, which are part of the intrinsic pathway of the clotting cascade. APTT is a test that measures the intrinsic and common clotting cascades, but it does not include factor IX, so haemophilia B may not always show an abnormal APTT. PT measures the extrinsic and common pathways of the clotting cascade and is associated with factors I, II, V, VII, and X. Bleeding time measures platelet function, which is normal in haemophilia. Therefore, APTT may be raised, PT will be normal, and bleeding time will be normal in haemophilia.

Haemophilia is a genetic disorder that affects blood coagulation and is inherited in an X-linked recessive manner. It is possible for up to 30% of patients to have no family history of the condition. Haemophilia A is caused by a deficiency of factor VIII, while haemophilia B, also known as Christmas disease, is caused by a lack of factor IX.

The symptoms of haemophilia include haemoarthroses, haematomas, and prolonged bleeding after surgery or trauma. Blood tests can reveal a prolonged APTT, while the bleeding time, thrombin time, and prothrombin time are normal. However, up to 10-15% of patients with haemophilia A may develop antibodies to factor VIII treatment.

Overall, haemophilia is a serious condition that can cause significant bleeding and other complications. It is important for individuals with haemophilia to receive appropriate medical care and treatment to manage their symptoms and prevent further complications.

The initial impact of vitamin B12 deficiency is typically on the dorsal column, causing impairment in joint position and vibration perception before the onset of distal paraesthesia.

Vitamin B12 is essential for the development of red blood cells and the maintenance of the nervous system. It is absorbed through the binding of intrinsic factor, which is secreted by parietal cells in the stomach, and actively absorbed in the terminal ileum. A deficiency in vitamin B12 can be caused by pernicious anaemia, post gastrectomy, a vegan or poor diet, disorders or surgery of the terminal ileum, Crohn’s disease, or metformin use.

Symptoms of vitamin B12 deficiency include macrocytic anaemia, a sore tongue and mouth, neurological symptoms, and neuropsychiatric symptoms such as mood disturbances. The dorsal column is usually affected first, leading to joint position and vibration issues before distal paraesthesia.

Management of vitamin B12 deficiency involves administering 1 mg of IM hydroxocobalamin three times a week for two weeks, followed by once every three months if there is no neurological involvement. If a patient is also deficient in folic acid, it is important to treat the B12 deficiency first to avoid subacute combined degeneration of the cord.